EP4228643A1 - Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses - Google Patents
Composition and methods for the prevention and treatment of covid-19 and respiratory illnessesInfo
- Publication number
- EP4228643A1 EP4228643A1 EP21880683.4A EP21880683A EP4228643A1 EP 4228643 A1 EP4228643 A1 EP 4228643A1 EP 21880683 A EP21880683 A EP 21880683A EP 4228643 A1 EP4228643 A1 EP 4228643A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- administered
- range
- zinc
- vitamin
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000000241 respiratory effect Effects 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 11
- 230000002265 prevention Effects 0.000 title claims abstract description 8
- 208000025721 COVID-19 Diseases 0.000 title description 22
- 238000000034 method Methods 0.000 title description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 764
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 482
- 239000011701 zinc Substances 0.000 claims abstract description 393
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 393
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 382
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 382
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 382
- 239000011718 vitamin C Substances 0.000 claims abstract description 382
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims abstract description 241
- 229920000153 Povidone-iodine Polymers 0.000 claims abstract description 241
- 229960001621 povidone-iodine Drugs 0.000 claims abstract description 241
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims abstract description 226
- 229960004171 hydroxychloroquine Drugs 0.000 claims abstract description 226
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 58
- 239000000126 substance Substances 0.000 claims abstract description 39
- 239000000443 aerosol Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 210000002345 respiratory system Anatomy 0.000 claims description 201
- 238000012387 aerosolization Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 description 219
- 239000004480 active ingredient Substances 0.000 description 206
- 239000007921 spray Substances 0.000 description 199
- 239000003814 drug Substances 0.000 description 18
- 241001678559 COVID-19 virus Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 3
- 210000003300 oropharynx Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229940126532 prescription medicine Drugs 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 235000019195 vitamin supplement Nutrition 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000008382 alveolar damage Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present disclosure relates to the field of general medicine, respiratory medicine, intensive care, and infectious diseases.
- the present disclosure relates to a composition of matter and to a method for the prevention of coronavirus disease 2019 (COVID- 19) and respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites.
- COVID- 19 coronavirus disease 2019
- pathogens including viruses, bacteria, fungi, and parasites.
- SARS-CoV-2 The novel coronavirus SARS-CoV-2 was recognised to cause the coronavirus disease 2019 (COVID-19).
- SARS-CoV-2 and COVID-19 have recently spread rapidly across the globe. Tens of millions of people have been diagnosed with COVID-19, resulting in a staggering number of deaths.
- Existing data suggests that COVID- 19 has a mortality rate of approximately 1-2%, with a higher mortality rate among individuals with pre-existing comorbidities and in healthcare systems with suboptimal access to ventilatory support.
- Accumulating data suggests that the incubation period of SARS-CoV-2 is approximately 5-7 days, and a significant proportion of patients may remain asymptomatic or mildly symptomatic during the illness.
- COVID-19 causes a mild and mostly self-limiting illness
- severe pneumonia has been reported in about 5% of patients during the inflammation phase of the disease, thus leading to patients requiring supplemental oxygen and endotracheal ventilation.
- Data from post-mortem studies indicate extensive alveolar damage, fibrosis, and consolidation in lung tissues of COVID- 19 patients.
- the antiseptic povidone-iodine has rapid virucidal effects against SARS-CoV-2, while zinc inhibits replication of at least six coronaviruses (including SARS-CoV and others that cause common cold).
- coronaviruses including SARS-CoV and others that cause common cold.
- vitamin C is a widely used remedy during the COVID-19 pandemic.
- AU 2020/100641 discloses oral administration of vitamin C and zinc in addition to azithromycin and aspirin.
- AU 2020/100400 discloses the combination of lifestyle changes with oral administration of vitamin supplements and prescription medicines to reduce the risk of viral infections.
- the vitamin supplements administered include nicotinamide, resveratrol, vitamin D3, while the prescription medicine administered was doxycycline and metformin.
- US 2020/179367 discloses the administration of isomyosmine for the treatment of coronavirus infection.
- a disadvantage of administration through the oral route is the first-pass effect and the delayed onset of action while the key advantage of administering drugs through the oropharyngeal and tracheobronchial routes lies in its potentially rapid onset of action at the main mode of entry for respiratory pathogens.
- the present disclosure provides a composition of matter and a method for preventing respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites.
- This includes the SARS-CoV-2 virus and COVID- 19, the disease caused by the SARS-CoV-2 virus.
- An aspect of an embodiment of the disclosure relates to the administration of a combination of two or more pharmaceutical drugs or active ingredients by inhalation for a multipronged and multitargeted approach against the spread of COVID-19 in the respiratory system.
- the two or more drugs or active ingredients may be administered through the oropharyngeal and tracheobronchial routes.
- the two or more drugs or active ingredients may be provided in liquid or powder forms.
- Administration through the nasal, oropharyngeal and tracheobronchial routes can be through direct contact, aerosolization or nebulisation methods to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
- composition of matter for delivery of a therapeutic amount per day of two or more substances to a patient through an inhalation delivery system for prevention or treatment of respiratory illness wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
- the two or more substances may be delivered through the nasal tract, oropharyngeal tract, or the respiratory tract.
- the two or more substances selected may be hydroxychloroquine and povidone -iodine.
- the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of povidone -iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg.
- the two or more substances selected may be hydroxychloroquine and zinc.
- the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
- the two or more substances selected may be hydroxychloroquine and vitamin C.
- the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
- the two or more substances selected may be hydroxychloroquine, vitamin C, and zinc.
- the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg;
- the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg;
- the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
- the two or more substances selected may be povidone-iodine and vitamin C.
- the therapeutic amount per day of povidone-iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300- 400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
- the two or more substances selected may be povidone-iodine and zinc.
- the therapeutic amount per day of povidone-iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
- the two or more substances selected may be povidone-iodine, zinc, and vitamin C.
- the therapeutic amount per day of povidone- iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg;
- the therapeutic amount of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60- 80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg;
- the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
- the two or more substances selected may be zinc and vitamin C.
- the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
- the therapeutic amount per day of hydroxychloroquine may be 0.00001-800 mg.
- the therapeutic amount per day of hydroxychloroquine may be 1-800 mg.
- the therapeutic amount per day of povidone-iodine maybe 1-600 pg.
- the therapeutic amount per day of povidone-iodine is 89-356 pg.
- the therapeutic amount per day of zinc may be 0.00001-200 mg.
- the therapeutic amount per day of vitamin C may be 0.00001-2000 mg.
- the therapeutic amount per day of vitamin C may be 0.00001- 1000 mg.
- the inhalation delivery system may be selected from the group comprising of nebulisation, aerosolization and oral gargle.
- delivery may be carried out based on a dosing regimen.
- composition of two or more substances for use in the prevention or treatment of respiratory illness by inhalation wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
- composition comprising two or more substances selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine for preventing or treating respiratory illness, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
- the terms “plurality” and “a plurality” as used herein may include, for example, “multiple” or “two or more”.
- the terms “plurality” or “a plurality” may be used throughout the specification to describe two or more components, devices, elements, units, parameters, or the like.
- the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently. Unless otherwise indicated, use of the conjunction “or” as used herein is to be understood as inclusive (any or all of the stated options).
- any doses of medication discussed and disclosed in the present disclosure refers to the total dose of each medication to be administered per day.
- the total dose of each medication to be administered per day may be administered in a single dose a day or may be administered in multiple doses a day.
- the present combination therapy is focused on the administration or delivery of a combination of two or more substances by inhalation.
- the inhalation may be through the nasal, oropharyngeal and tracheobronchial routes.
- the substances may be pharmaceutical drugs or active ingredients.
- Delivery of a therapeutic agent by inhalation to the respiratory system using an inhalation delivery system allows for a direct delivery of medication to where the medication is needed and avoids the first-pass effect with minimum reduction of bioavailability.
- the large surface area in the pulmonary region facilitates rapid absorption of the delivered drug from the alveolar region to the blood.
- aerosol delivery is non-invasive, a much lower dose of medications is required to achieve the same efficacy compared to oral administration.
- the two or more pharmaceutical drugs or active ingredients may be administered through the nasal, oropharyngeal or the tracheobronchial tract.
- the two or more pharmaceutical drugs or active ingredients may be delivered to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
- the two or more pharmaceutical drugs or active ingredients may be administered through therapeutic inhalation delivery systems which facilitate the transport and deposition of drugs in the human respiratory tract.
- the therapeutic inhalation delivery systems may be a pressurised metered-dose inhaler (MDI), a dry powder inhaler, a medical nebuliser, a solution mist inhaler, or an oral/nasal spray.
- the therapeutic inhalation delivery system may differ depending on several factors, including particle characteristics (e.g., particle size, shape, density, charge and hygroscopicity), airway geometry (due to age, gender, and disease status), and breathing pattern (e.g., frequency, tidal volume, and breath-holding time).
- particle characteristics e.g., particle size, shape, density, charge and hygroscopicity
- airway geometry due to age, gender, and disease status
- breathing pattern e.g., frequency, tidal volume, and breath-holding time
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, povidone-iodine, zinc, or vitamin C.
- hydroxychloroquine may be administered within a range of 0.00001-800 mg per day, and preferably within a range of 1-800 mg per day.
- povidone- iodine may be administered within a range of 1-600 pg a day.
- povidone-iodine may be administered within a range of 1-4 sprays of a commercially available spray, which may amount to a range of 89-356 pg of povidone-iodine.
- zinc may be administered within a range of 0.00001-200 mg per day.
- vitamin C may be administered within a range of 0.00001-2000 mg per day, and preferably within a range of 0.00001-1000 mg per day.
- the composition may be hydroxychloroquine with povidone-iodine, hydroxychloroquine with zinc, hydroxychloroquine with vitamin C, hydroxychloroquine with vitamin C and zinc, povidone- iodine with vitamin C, povidone-iodine with zinc, povidone-iodine with zinc and vitamin C, or zinc with vitamin C.
- the dosage range may vary depending on several factors, including the therapeutic delivery system employed and characteristics of the recipient.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- povidone-iodine may be administered within a range of 1- 100 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- povidone-iodine may be administered within a range of 100-200 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 200-300 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- povidone-iodine may be administered within a range of 300-400 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- povidone-iodine may be administered within a range of 400-500 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- povidone-iodine may be administered within a range of 500-600 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 1-10 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 1-10 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 1-10 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 1-10 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 1-10 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 20-40 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 40-60 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 60-80 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 80-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 100-125 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 125-150 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 150-175 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 0.00001- 1 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 1- 100 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 100- 200 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 200- 400 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 400- 600 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 600- 800 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc.
- Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- zinc may be administered within a range of 175-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C.
- Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 0.00001-1 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 1- 100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 1- 100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 1- 100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 1- 100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 1- 100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 1-100 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 100- 200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 100-200 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 200- 400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 200-400 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 400- 600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 400-600 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1-10 mg
- vitamin C may be administered within a range of 600- 800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 600-800 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 0.00001-1 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 1- 10 mg
- vitamin C may be administered within a range of 800- 1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 10-20 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 20-40 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 40-60 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 60-80 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 80-100 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 100-125 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 125-150 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 150-175 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C.
- Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg
- zinc may be administered within a range of 175-200 mg
- vitamin C may be administered within a range of 800-1,000 mg
- the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range ofO.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C.
- Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg
- vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
- the two or more pharmaceutical drugs or active ingredients may be administered according to a dosage regimen, including administration one or more times a day.
- a dosage regimen including administration one or more times a day.
- the dosage regimen may vary depending on several factors, including the therapeutic delivery system employed, the pharmaceutical drug or active ingredient administered.
Abstract
A composition of matter, and use of the composition, for delivery of a therapeutic amount per day of two or more substances to a patient through an inhalation delivery system for prevention or treatment of respiratory illness, wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
Description
COMPOSITION AND METHODS FOR THE PREVENTION AND TREATMENT OF COVID- 19 AND RESPIRATORY ILLNESSES
TECHNICAL FIELD
[0001] The present disclosure relates to the field of general medicine, respiratory medicine, intensive care, and infectious diseases. In particular, the present disclosure relates to a composition of matter and to a method for the prevention of coronavirus disease 2019 (COVID- 19) and respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites.
BACKGROUND
[0002] The novel coronavirus SARS-CoV-2 was recognised to cause the coronavirus disease 2019 (COVID-19). SARS-CoV-2 and COVID-19 have recently spread rapidly across the globe. Tens of millions of people have been diagnosed with COVID-19, resulting in a staggering number of deaths. Existing data suggests that COVID- 19 has a mortality rate of approximately 1-2%, with a higher mortality rate among individuals with pre-existing comorbidities and in healthcare systems with suboptimal access to ventilatory support. Accumulating data suggests that the incubation period of SARS-CoV-2 is approximately 5-7 days, and a significant proportion of patients may remain asymptomatic or mildly symptomatic during the illness. Although COVID-19 causes a mild and mostly self-limiting illness, severe pneumonia has been reported in about 5% of patients during the inflammation phase of the disease, thus leading to patients requiring supplemental oxygen and endotracheal ventilation. Data from post-mortem studies indicate extensive alveolar damage, fibrosis, and consolidation in lung tissues of COVID- 19 patients.
[0003] Existing containment measures against SARS-CoV-2 centre around mask wearing, hand hygiene and physical distancing, which require a collective effort of an entire community to remain effective. Although the availability of an effective vaccine is highly anticipated, uncertainties surrounding their efficacy, safety, and accessibility limit their appeal to those who are presently at risk of COVID-19. It is also unclear how soon host immunity could be triggered following vaccination and whether vaccination results in a lifelong immunity. For individuals
living in an environment that confers a high-risk of developing COVID-19 (e.g., healthcare workers, quarantined individuals, household contacts, individuals living in a closed environment with an active cluster), there is a need for a preventive solution that could lower the incidence of COVID-19. This solution should be simple and safe to administer, and efficacious in interrupting replication of SARS-CoV-2.
[0004] Furthermore, there is presently no proven pharmacologic drug that has been shown to reduce the risk of COVID- 19 transmission. Although studies have tested the efficacy of different drugs against COVID-19, none has been conclusively shown to reduce the spread of the disease. Hydroxychloroquine, an antiparasitic drug, has been shown to reduce affinity of SARS-CoV-2 to the angiotensin-converting-enzyme 2 receptors in vitro. Hydroxychloroquine inhibits SARS-CoV-2 infection of Vero cells by elevating endosomal pH. The antiseptic povidone-iodine has rapid virucidal effects against SARS-CoV-2, while zinc inhibits replication of at least six coronaviruses (including SARS-CoV and others that cause common cold). Despite a lack in preclinical evidence against coronaviruses, vitamin C is a widely used remedy during the COVID-19 pandemic.
[0005] A prior study on the efficacy of administration of hydroxychloroquine, povidone-iodine, zinc/vitamin C and vitamin C carried out in high-risk individuals living in a closed quarantine setting showed positive results. In this study, each participant received only one treatment. Hydroxychloroquine, zinc/vitamin C and vitamin C were administered through the oral route while povidone-iodine was administered by throat spray to the oropharynx. Response to these different treatments was varied with positive effects observed, the positive effects varying according to the type of treatment and compliance to study medication. The frequency of SARS-CoV-2 infection was significantly lower in participants receiving hydroxychloroquine, povidone-iodine and zinc/vitamin combination as compared to participants receiving only vitamin C. In addition, participants who received prophylaxis intervention reported fewer respiratory symptoms and participants with SARS-CoV-2 infection had fewer symptoms compared with those who received only vitamin C. This study, however, did not evaluate whether the efficacy of these medications would improve when used in combination and when administered directly to the oropharyngeal and respiratory routes.
[0006] Finally, previous studies mostly administered pharmaceutical agents through the oral route; no studies have examined the feasibility of administering pharmaceutical agents through the oropharyngeal and tracheobronchial routes. AU 2020/100641 discloses oral administration
of vitamin C and zinc in addition to azithromycin and aspirin. AU 2020/100400 discloses the combination of lifestyle changes with oral administration of vitamin supplements and prescription medicines to reduce the risk of viral infections. The vitamin supplements administered include nicotinamide, resveratrol, vitamin D3, while the prescription medicine administered was doxycycline and metformin. Finally, US 2020/179367 discloses the administration of isomyosmine for the treatment of coronavirus infection. A disadvantage of administration through the oral route is the first-pass effect and the delayed onset of action while the key advantage of administering drugs through the oropharyngeal and tracheobronchial routes lies in its potentially rapid onset of action at the main mode of entry for respiratory pathogens.
SUMMARY
[0007] Briefly stated, the present disclosure provides a composition of matter and a method for preventing respiratory tract infections arising from pathogens including viruses, bacteria, fungi, and parasites. This includes the SARS-CoV-2 virus and COVID- 19, the disease caused by the SARS-CoV-2 virus. An aspect of an embodiment of the disclosure relates to the administration of a combination of two or more pharmaceutical drugs or active ingredients by inhalation for a multipronged and multitargeted approach against the spread of COVID-19 in the respiratory system. The two or more drugs or active ingredients may be administered through the oropharyngeal and tracheobronchial routes. The two or more drugs or active ingredients may be provided in liquid or powder forms. Administration through the nasal, oropharyngeal and tracheobronchial routes can be through direct contact, aerosolization or nebulisation methods to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
[0008] There is provided according to some embodiments of the disclosure, a composition of matter for delivery of a therapeutic amount per day of two or more substances to a patient through an inhalation delivery system for prevention or treatment of respiratory illness, wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol. Optionally, the two or more substances may be delivered through the nasal tract, oropharyngeal tract, or the respiratory tract.
[0009] According to some embodiments, the two or more substances selected may be hydroxychloroquine and povidone -iodine. Optionally, the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of povidone -iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg.
[0010] According to some embodiments, the two or more substances selected may be hydroxychloroquine and zinc. Optionally, the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
[0011] According to some embodiments, the two or more substances selected may be hydroxychloroquine and vitamin C. Optionally, the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
[0012] According to some embodiments, the two or more substances selected may be hydroxychloroquine, vitamin C, and zinc. Optionally, the therapeutic amount per day of hydroxychloroquine may be selected from the group comprising of 1-10 mg, 10-50 mg, 50- 100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400-600 mg, and 600-800 mg; the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
[0013] According to some embodiments, the two or more substances selected may be povidone-iodine and vitamin C. Optionally, the therapeutic amount per day of povidone-iodine
may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300- 400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
[0014] According to some embodiments, the two or more substances selected may be povidone-iodine and zinc. Optionally, the therapeutic amount per day of povidone-iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
[0015] According to some embodiments, the two or more substances selected may be povidone-iodine, zinc, and vitamin C. Optionally, the therapeutic amount per day of povidone- iodine may be selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; the therapeutic amount of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60- 80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
[0016] According to some embodiments, the two or more substances selected may be zinc and vitamin C. Optionally, the therapeutic amount per day of zinc may be selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C may be selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800-1000 mg.
[0017] According to some embodiments, the therapeutic amount per day of hydroxychloroquine may be 0.00001-800 mg. Optionally, the therapeutic amount per day of hydroxychloroquine may be 1-800 mg.
[0018] According to some embodiments, the therapeutic amount per day of povidone-iodine maybe 1-600 pg. Optionally, the therapeutic amount per day of povidone-iodine is 89-356 pg.
[0019] According to some embodiments, the therapeutic amount per day of zinc may be 0.00001-200 mg.
[0020] According to some embodiments, the therapeutic amount per day of vitamin C may be 0.00001-2000 mg. Optionally, the therapeutic amount per day of vitamin C may be 0.00001- 1000 mg.
[0021] According to some embodiments, the inhalation delivery system may be selected from the group comprising of nebulisation, aerosolization and oral gargle.
[0022] According to some embodiments, delivery may be carried out based on a dosing regimen.
[0023] There is further provided according to some embodiments of the disclosure, a composition of two or more substances for use in the prevention or treatment of respiratory illness by inhalation, wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
[0024] There is further provided according to some embodiments of the disclosure, use of a composition comprising two or more substances selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine for preventing or treating respiratory illness, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
DETAILED DESCRIPTION OF THE INVENTION
[0025] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those of ordinary skill in the art that the invention may be practiced without these specific details. In other instances, well-known methods, procedures, components, modules, units and/or circuits have not been described in detail so as not to obscure the invention.
[0026] Although embodiments of the invention are not limited in this regard, the terms “plurality” and “a plurality” as used herein may include, for example, “multiple” or “two or more”. The terms “plurality” or “a plurality” may be used throughout the specification to
describe two or more components, devices, elements, units, parameters, or the like. Unless explicitly stated, the method embodiments described herein are not constrained to a particular order or sequence. Additionally, some of the described method embodiments or elements thereof can occur or be performed simultaneously, at the same point in time, or concurrently. Unless otherwise indicated, use of the conjunction “or” as used herein is to be understood as inclusive (any or all of the stated options).
[0027] For the avoidance of doubt, and unless specified to the contrary, any doses of medication discussed and disclosed in the present disclosure refers to the total dose of each medication to be administered per day. The total dose of each medication to be administered per day may be administered in a single dose a day or may be administered in multiple doses a day.
[0028] The present combination therapy is focused on the administration or delivery of a combination of two or more substances by inhalation. The inhalation may be through the nasal, oropharyngeal and tracheobronchial routes. The substances may be pharmaceutical drugs or active ingredients. Delivery of a therapeutic agent by inhalation to the respiratory system using an inhalation delivery system allows for a direct delivery of medication to where the medication is needed and avoids the first-pass effect with minimum reduction of bioavailability. In addition, the large surface area in the pulmonary region facilitates rapid absorption of the delivered drug from the alveolar region to the blood. As aerosol delivery is non-invasive, a much lower dose of medications is required to achieve the same efficacy compared to oral administration.
[0029] In some embodiments of the present disclosure, the two or more pharmaceutical drugs or active ingredients may be administered through the nasal, oropharyngeal or the tracheobronchial tract. The two or more pharmaceutical drugs or active ingredients may be delivered to the nasal, nasopharynx, oropharynx, and tracheobronchial spaces.
[0030] In some embodiments of the present disclosure, the two or more pharmaceutical drugs or active ingredients may be administered through therapeutic inhalation delivery systems which facilitate the transport and deposition of drugs in the human respiratory tract. The therapeutic inhalation delivery systems may be a pressurised metered-dose inhaler (MDI), a dry powder inhaler, a medical nebuliser, a solution mist inhaler, or an oral/nasal spray. The person skilled in the art would appreciate that the therapeutic inhalation delivery system may differ depending on several factors, including particle characteristics (e.g., particle size, shape,
density, charge and hygroscopicity), airway geometry (due to age, gender, and disease status), and breathing pattern (e.g., frequency, tidal volume, and breath-holding time).
[0031] In some embodiments of the present disclosure, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, povidone-iodine, zinc, or vitamin C. In some embodiments, hydroxychloroquine may be administered within a range of 0.00001-800 mg per day, and preferably within a range of 1-800 mg per day. In some embodiments, povidone- iodine may be administered within a range of 1-600 pg a day. In some embodiments, povidone-iodine may be administered within a range of 1-4 sprays of a commercially available spray, which may amount to a range of 89-356 pg of povidone-iodine. In some embodiments, zinc may be administered within a range of 0.00001-200 mg per day. In some embodiments, vitamin C may be administered within a range of 0.00001-2000 mg per day, and preferably within a range of 0.00001-1000 mg per day. In some embodiments, the composition may be hydroxychloroquine with povidone-iodine, hydroxychloroquine with zinc, hydroxychloroquine with vitamin C, hydroxychloroquine with vitamin C and zinc, povidone- iodine with vitamin C, povidone-iodine with zinc, povidone-iodine with zinc and vitamin C, or zinc with vitamin C. The person skilled in the art would appreciate that the dosage range may vary depending on several factors, including the therapeutic delivery system employed and characteristics of the recipient.
[0032] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 1- 100 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0033] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 100-200 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0034] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 200-300 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0035] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 300-400 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0036] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 400-500 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0037] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and povidone-iodine. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, povidone-iodine may be administered within a range of 500-600 pg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0038] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0039] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0040] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0041] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0042] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0043] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0044] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0045] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0046] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0047] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0048] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-400 mg, 400- 600 mg, 600-800 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0049] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0050] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0051] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0052] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0053] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0054] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0055] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine and vitamin C. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0056] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0057] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0058] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may
be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0059] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0060] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0061] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0062] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0063] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0064] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0065] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0066] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0067] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-
400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0068] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0069] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0070] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0071] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 20-40 mg, and the combination may be
administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0072] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0073] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0074] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0075] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0076] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0077] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0078] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0079] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0080] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-
400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0081] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0082] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0083] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0084] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 60-80 mg, and the combination may be
administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0085] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0086] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0087] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0088] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0089] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0090] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0091] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0092] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0093] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-
400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0094] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0095] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0096] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0097] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 80-100 mg, and the combination may
be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0098] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0099] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0100] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0101] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0102] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0103] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0104] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0105] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0106] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-
400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0107] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0108] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0109] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0110] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 125-150 mg, and the combination may be
administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0111] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0112] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0113] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0114] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0115] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0116] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0117] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0118] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0119] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300-
400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 0.00001- 1 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0120] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 1- 100 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0121] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 100- 200 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0122] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 200- 400 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0123] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 400- 600 mg, zinc may be administered within a range of 175-200 mg, and the combination may be
administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0124] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 600- 800 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0125] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be hydroxychloroquine, vitamin C and zinc. Hydroxychloroquine may be administered within a range of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, 600-800 mg, vitamin C may be administered within a range of 800- 1,000 mg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0126] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0127] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0128] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0129] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0130] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0131] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0132] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and vitamin C. Povidone-iodine may be administered within a range of 1- 100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0133] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0134] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0135] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0136] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0137] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0138] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0139] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0140] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0141] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0142] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0143] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine and zinc. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0144] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0145] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0146] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of
0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0147] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0148] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0149] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0150] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0151] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of
0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0152] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0153] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0154] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 0.00001-1 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0155] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0156] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 1-
100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0157] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0158] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0159] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0160] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 1- 100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0161] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of
1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0162] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0163] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0164] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0165] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0166] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range
of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0167] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 100- 200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0168] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0169] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0170] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0171] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of
100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0172] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0173] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0174] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0175] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0176] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of
100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0177] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0178] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 200- 400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0179] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0180] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0181] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of
200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0182] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0183] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0184] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0185] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0186] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of
200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0187] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0188] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0189] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 400- 600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0190] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0191] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of
400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0192] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0193] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0194] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0195] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0196] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of
400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0197] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0198] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0199] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0200] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1-10 mg, vitamin C may be administered within a range of 600- 800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0201] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of
600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0202] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0203] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0204] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0205] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0206] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of
600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0207] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0208] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0209] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 600-800 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0210] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 0.00001-1 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0211] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 1- 10 mg, vitamin C may be administered within a range of 800-
1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0212] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 10-20 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0213] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 20-40 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0214] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 40-60 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0215] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 60-80 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0216] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 80-100 mg, vitamin C may be administered within a range of
800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0217] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 100-125 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0218] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 125-150 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0219] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 150-175 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0220] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be povidone-iodine, zinc and vitamin C. Povidone-iodine may be administered within a range of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, 500-600 pg, zinc may be administered within a range of 175-200 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0221] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range ofO.00001-1 mg, and the
combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0222] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 1-100 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0223] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 100-200 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0224] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 200-400 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0225] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 400-600 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0226] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 600-800 mg, and the
combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0227] In some embodiments, the two or more pharmaceutical drugs or active ingredients may be zinc and vitamin C. Zinc may be administered within a range of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150— 175 mg, 175-200 mg, vitamin C may be administered within a range of 800-1,000 mg, and the combination may be administered per day, orally and/or by spray applied to the nasal, oropharyngeal or respiratory systems.
[0228] In some embodiments of the present disclosure, the two or more pharmaceutical drugs or active ingredients may be administered according to a dosage regimen, including administration one or more times a day. The person skilled in the art would appreciate that the dosage regimen may vary depending on several factors, including the therapeutic delivery system employed, the pharmaceutical drug or active ingredient administered.
[0229] Different embodiments are disclosed herein. Features of certain embodiments may be combined with features of other embodiments; thus, certain embodiments may be combinations of features of multiple embodiments. The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. It should be appreciated by persons skilled in the art that many modifications, variations, substitutions, changes, and equivalents are possible in light of the above teaching. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
[0230] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims
1. A composition of matter for delivery of a therapeutic amount per day of two or more substances to a patient through an inhalation delivery system for prevention or treatment of respiratory illness, wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
2. The composition of claim 1, wherein the two or more substances are delivered through the nasal tract, oropharyngeal tract, or the respiratory tract.
3. The composition of claim 1 or 2, wherein the two or more substances selected are hydroxychloroquine and povidone-iodine.
4. The composition of claim 3, wherein: the therapeutic amount per day of hydroxychloroquine is selected from the group comprising of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of povidone-iodine is selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg.
5. The composition of claim 1 or 2, wherein the two or more substances selected are hydroxychloroquine and zinc.
6. The composition of claim 5, wherein: the therapeutic amount per day of hydroxychloroquine is selected from the group comprising of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of zinc is selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
7. The composition of claim 1 or 2, wherein the two or more substances selected are hydroxychloroquine and vitamin C.
8. The composition of claim 7, wherein: the therapeutic amount per day of hydroxychloroquine is selected from the group comprising of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, and 600-800 mg; and the therapeutic amount per day of vitamin C is selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
9. The composition of claim 1 or 2, wherein the two or more substances selected are hydroxychloroquine, vitamin C, and zinc.
10. The composition of claim 9, wherein: the therapeutic amount per day of hydroxychloroquine is selected from the group comprising of 1-10 mg, 10-50 mg, 50-100 mg, 100-150 mg, 150-200 mg, 200-300 mg, 300- 400 mg, 400-600 mg, and 600-800 mg; the therapeutic amount per day of vitamin C is selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg; and the therapeutic amount per day of zinc is selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
11. The composition of claim 1 or 2, wherein the two or more substances selected are povidone-iodine and vitamin C.
12. The composition of claim 11, wherein: the therapeutic amount per day of povidone-iodine is selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of vitamin C is selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
13. The composition of claim 1 or 2, wherein the two or more substances selected are povidone-iodine and zinc.
14. The composition of claim 13, wherein: the therapeutic amount per day of povidone -iodine is selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; and the therapeutic amount per day of zinc is selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg.
15. The composition of claim 1 or 2, wherein the two or more substances selected are povidone-iodine, zinc, and vitamin C.
16. The composition of claim 15, wherein: the therapeutic amount per day of povidone-iodine is selected from the group comprising of 1-100 pg, 100-200 pg, 200-300 pg, 300-400 pg, 400-500 pg, and 500-600 pg; the therapeutic amount of zinc is selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C is selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
17. The composition of claim 1 or 2, wherein the two or more substances selected are zinc and vitamin C.
18. The composition of claim 17, wherein: the therapeutic amount per day of zinc is selected from the group comprising of 0.00001-1 mg, 1-10 mg, 10-20 mg, 20-40 mg, 40-60 mg, 60-80 mg, 80-100 mg, 100-125 mg, 125-150 mg, 150-175 mg, and 175-200 mg; and the therapeutic amount per day of vitamin C is selected from the group comprising of 0.00001-1 mg, 1-100 mg, 100-200 mg, 200-400 mg, 400-600 mg, 600-800 mg, and 800- 1000 mg.
19. The composition of claim 1 or 2, wherein the therapeutic amount per day of hydroxychloroquine is 0.00001-800 mg.
20. The composition of any of claims 1, 2 or 19, wherein the therapeutic amount per day of hydroxychloroquine is 1-800 mg.
21. The composition of claim 1 or 2, wherein the therapeutic amount per day of povidone- iodine is 1-600 pg.
22. The composition of any of claims 1, 2 or 21, wherein the therapeutic amount per day of povidone -iodine is 89-356 pg.
23. The composition of claim 1 or 2, wherein the therapeutic amount per day of zinc is 0.00001-200 mg.
24. The composition of claim 1 or 2, wherein the therapeutic amount per day of vitamin C is 0.00001-2000 mg.
25. The composition of any of claims 1, 2 or 24, wherein the therapeutic amount per day of vitamin C is 0.00001-1000 mg.
26. The composition of any of claims 1 to 25, wherein the inhalation delivery system is selected from the group comprising of nebulisation, aerosolization and oral gargle.
27. The composition of any of claims 1 to 26, wherein delivery is carried out based on a dosing regimen.
28. A composition of two or more substances for use in the prevention or treatment of respiratory illness by inhalation, wherein the two or more substances are selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
29. Use of a composition comprising two or more substances selected from the group comprising of hydroxychloroquine, zinc, vitamin C and povidone-iodine for preventing or treating respiratory illness, characterized in that the two or more substances are in a form selected from the group comprising of liquid, powder, and aerosol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10202010250W | 2020-10-15 | ||
PCT/SG2021/050621 WO2022081093A1 (en) | 2020-10-15 | 2021-10-14 | Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4228643A1 true EP4228643A1 (en) | 2023-08-23 |
Family
ID=81209491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21880683.4A Pending EP4228643A1 (en) | 2020-10-15 | 2021-10-14 | Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4228643A1 (en) |
WO (1) | WO2022081093A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
JP2002059700A (en) * | 2000-08-22 | 2002-02-26 | Osaka Prefecture | Rainbow color developing working method |
US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
US20080138397A1 (en) * | 2006-10-24 | 2008-06-12 | Aradigm Corporation | Processes for taste-masking of inhaled formulations |
JOP20120023B1 (en) * | 2011-02-04 | 2022-03-14 | Novartis Ag | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
JP6955784B2 (en) * | 2017-07-04 | 2021-10-27 | フルケム リミテッドFluchem Ltd | An antiviral and antibacterial composition for eyes, oral cavity, nasal cavity or inhalation containing a solid composition containing an iodo agent and sodium chloride having improved water solubility and an aqueous solution thereof. |
CN111297838A (en) * | 2020-04-08 | 2020-06-19 | 宁波合康生物医药科技有限公司 | Inhalation spray of antiviral drug |
EP3892275A1 (en) * | 2020-04-08 | 2021-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hcq or its metabolites for the treatment of lung infections |
-
2021
- 2021-10-14 WO PCT/SG2021/050621 patent/WO2022081093A1/en unknown
- 2021-10-14 EP EP21880683.4A patent/EP4228643A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2022081093A1 (en) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5543434A (en) | Nasal administration of ketamine to manage pain | |
Devidayal et al. | Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma | |
Storr et al. | Nebulised beclomethasone dipropionate in preschool asthma. | |
KR20150096370A (en) | Anxiolytic composition, formulation and method of use | |
CN108040468B (en) | Preparation for treating oral cavity, throat and respiratory diseases | |
US20230158259A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
Direkwatanachai et al. | Comparison of salbutamol efficacy in children-via the metered-dose inhaler (MDI) with Volumatic? spacer and via the dry powder inhaler, Easyhaler?, with the nebulizer-in mild to moderate asthma exacerbation: a multicenter, randomized study | |
CN112791097A (en) | Application of iodine in preparing medicament for preventing and treating respiratory infectious diseases and method for preparing low-particle-size iodine-containing aerosol | |
MX2014002125A (en) | Treatment of symptoms associated with female gastroparesis. | |
US20130216574A1 (en) | Kit providing multiple unmet therapeutic effects | |
EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
EP4228643A1 (en) | Composition and methods for the prevention and treatment of covid-19 and respiratory illnesses | |
CA2506962A1 (en) | Synergistic combination comprising roflumilast and formoterol | |
AU2020103517A4 (en) | Ibp- nebulizer: intelligent nebulizer for bronchitis patients | |
Amar et al. | Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthma. | |
Poulakou et al. | Inhaled antimicrobials for ventilator-associated pneumonia: practical aspects | |
WO2022063320A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
Tomić et al. | Medications and non-pharmacological measures to alleviate the symptoms of respiratory tract infections in the pediatric population | |
JPH05201861A (en) | Reinforcement of anti-tussis effect of dexthorphan | |
EP1567140B1 (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
WO2010009288A1 (en) | Compositions and uses of antiviral active pharmaceutical agents | |
Erelel et al. | Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics 2021, 13, 1768 | |
Cochrane | Acute severe asthma: oxygen and high dose beta agonist during transfer for all? | |
Ballard et al. | Assessment of bronchodilator response to a β-adrenergic delivered from an ultrasonic nebulizer | |
US20230201309A1 (en) | Compositions for the treatment of a respiratory condition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230330 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |